<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20241018063404N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-01-08</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>Comparison of the efficacy of laser therapy versus medical therapy for the treatment of infraorbital dark circles</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the efficacy of Alexandrite laser therapy versus medical therapy for the treatment of infraorbital dark circles in patients of dermatology clinic</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>102</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/79723</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Blinding description: In this study, a single-blind method has been used. In this approach, participants are unaware of the group allocation. This design was intentionally implemented to prevent any potential bias or psychological influence in the assessment of outcomes.</study_design>
      <phase>2</phase>
      <hc_freetext>Infraorbital dark circles.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group One: The first intervention group consists of 51 individuals who presented with complaints of dark circles under the eyes at Dr. Tehrani's dermatology clinic in Tehran. This group will receive treatment using the Alexandrite laser from Cynosure Elite, an American-made device operating at a wavelength of 755 nm. Participants in this group will undergo treatment over four sessions, spaced 1.5 months apart. During the treatment period, participants will be permitted to use only under-eye sunscreen. Intervention 2: Intervention group Two: Intervention Group Two: The second intervention group comprises 51 individuals who presented with complaints of dark circles under the eyes at Dr. Tehrani's dermatology clinic in Tehran. This group will receive treatment with a modified formulation of the Kligman formula, consisting of a 0.1% betamethasone cream, a 5% hydroquinone cream and a 0.05% tretinoin cream. Participants are required to apply a lentil-sized amount of this topical combination under the eyes every night for a duration of six months. Throughout the treatment period, participants will be permitted to use only the prescribed medications and an under-eye sunscreen.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The individual data of participants in this study will be shared only after ensuring that the identities of individuals are rendered unidentifiable, thereby preserving the privacy of all participants.

When:
The dissemination of these documents/data files will occur upon the complete conclusion of the research project. In the event that the project is published as a manuscript, access to the data will be granted following the completion of the publication process, and will remain available for a period of up to two years after the article's publication.

To whom:
Due to the practical relevance of the project's subject matter in the fields of medicine, industry, and aesthetics, access will be granted to individuals who submit requests and are approved and deemed qualified by the project team.

Conditions:
Any utilization of the data from this study must be coordinated with the project team responsible for its execution and accompanied by a written permission statement from the research team to ensure the preservation of publication rights.

Where to obtain:
Applicants may contact us via email at the following address (or at a subsequently provided address in the event of any changes): s2000.edu.khoram@gmail.com.

How to obtain:
Initially, you are required to introduce yourself and your research group in your email. Following this, please provide a comprehensive description of how the data will be utilized and the specific methodologies involved. It is essential to clearly and explicitly articulate the objectives of using the data. Subsequently, necessary arrangements will be coordinated with you by the project team.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sama Khoraminejad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>3th Floor, No. 48, Shahid Maleki Alley, West 160 St., Rashid Ave., Tehran Pars</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1653959564</zip>
        <telephone>+98 21 7788 2168</telephone>
        <email>s2000.edu.khoram@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sama Khoraminejad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>3th Floor, No. 48, Shahid Maleki Alley, West 160 St., Rashid Ave., Tehran Pars</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1653959564</zip>
        <telephone>+98 21 7788 2168</telephone>
        <email>s2000.edu.khoram@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients having darkness under the eyes referring to the skin clinic
Consent to participate in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Refusal to continue participating in the study
Severe medical complication</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group One: The first intervention group consists of 51 individuals who presented with complaints of dark circles under the eyes at Dr. Tehrani's dermatology clinic in Tehran. This group will receive treatment using the Alexandrite laser from Cynosure Elite, an American-made device operating at a wavelength of 755 nm. Participants in this group will undergo treatment over four sessions, spaced 1.5 months apart. During the treatment period, participants will be permitted to use only under-eye sunscreen.</i_keyword>
      <i_keyword>Intervention group Two: Intervention Group Two: The second intervention group comprises 51 individuals who presented with complaints of dark circles under the eyes at Dr. Tehrani's dermatology clinic in Tehran. This group will receive treatment with a modified formulation of the Kligman formula, consisting of a 0.1% betamethasone cream, a 5% hydroquinone cream and a 0.05% tretinoin cream. Participants are required to apply a lentil-sized amount of this topical combination under the eyes every night for a duration of six months. Throughout the treatment period, participants will be permitted to use only the prescribed medications and an under-eye sunscreen.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Infraorbital pigmentation score. Timepoint: Measurement of under-eye pigmentation was conducted at the onset of the study (prior to the initiation of the intervention) and again six months following the commencement of treatment. Method of measurement: Measurement of pigmentation device; Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-10-09</approval_date>
        <contact_name>Research Ethics Committees of Tehran Islamic Azad University Of Medical Sciences</contact_name>
        <contact_address>3th Floor, No. 48, Shahid Maleki Alley, West 160 St., Rashid Ave., Tehran Pars Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
